Results 71 to 80 of about 8,627 (176)
American Journal of Hematology, Volume 101, Issue 7, Page 1628-1631, July 2026.
Rasmus W. Green +2 more
wiley +1 more source
The Effect of Ecopipam on the Pharmacokinetics of Concomitant Medications
Clinical and Translational Science, Volume 19, Issue 2, February 2026.ABSTRACT Ecopipam is a first‐in‐class dopamine D1 receptor antagonist under investigation for the treatment of Tourette syndrome. This open‐label, fixed‐sequence, three‐cohort study evaluated whether ecopipam induces or inhibits cytochrome P450 (CYP) 1A2, CYP2B6, CYP2C19, CYP2D6, CYP3A4, organic anion‐transporting polypeptide (OATP) 1B1, and p ...
Virginia D. Schmith +4 more
wiley +1 more source
Advanced Science, Volume 13, Issue 2, 9 January 2026.The advent of aptamers has highlighted their potential as alternatives to antibodies, overcoming limitations of structural instability and production cost. However, conventional approaches such as SELEX remain slow and labor‐intensive. This review examines recent advances in aptamer engineering, emphasizing in vitro and AI‐driven in silico strategies ...
John V. L. Nguyen +5 more
wiley +1 more source
Neck‐vein thrombosis during spaceflight
British Journal of Clinical Pharmacology, Volume 92, Issue 1, Page 24-34, January 2026.Spaceflight imposes unique environmental challenges, including weightlessness, increased radiation exposure and confinement, which can lead to unexpected health effects. One such example is neck‐vein thrombosis, a condition rarely seen on Earth without predisposing factors such as venous catheters or infections.
Ulrich Limper, Jens Jordan
wiley +1 more source
Physiologically‐Based Pharmacokinetic Modeling of the PARP Inhibitor Niraparib
CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 1, January 2026.ABSTRACT A physiologically‐based pharmacokinetic (PBPK) model of niraparib and its primary metabolite using a relevant virtual cancer population is reported here. A series of in vitro experiments using liver S9, microsomes, and hepatocytes with various inhibitors and recombinant supersomes demonstrated that niraparib is specifically metabolized by ...
Gareth J. Lewis +3 more
wiley +1 more source
Dabigatran etexilate and reduction in serum apolipoprotein B
, 2016 Objective Carboxylesterases, which convert dabigatran etexilate to its active form, dabigatran, have also been shown to influence lipoprotein metabolism, although any pleotropic effects of the drug based on this possible mechanism has not been evaluated.
Wallentin, Lars, +11 more
core +1 more source
Patient safety and estimation of renal function in patients prescribed new oral anticoagulants for stroke prevention in atrial fibrillation [PDF]
, 2013 Hull, SA +6 more
core +4 more sources
Warfarin versus dabigatran etexilate: an assessment of efficacy and safety in patients with atrial fibrillation [PDF]
, 2015 dabigatran etexilate, warfarin, oral anticoagulation, atrial fibrillation, efficacy, safety.Introduction Oral anticoagulation is the mainstay for stroke and thromboembolic events prevention in patients with atrial fibrillation (AF).
Dzeshka, M. S., Lip, G. Y.
core
The effects of dabigatran etexilate on fracture healing in rats An experimental study
, 2015 Yenilmez, Engin/0000-0002-0755-4394; Kerimoglu, Gokcen/0000-0002-4349-7796Background: Deep vein thrombosis leading to pulmonary embolism is one of the major complication after fracture. After a fracture occurs, the coagulation cascade activates thrombin,
Onay, Atılgan +5 more
core +1 more source
, 2010 Patients with atrial fibrillation at moderate to high risk of stroke are not always anticoagulated despite a lack of contraindications to vitamin K antagonists (VKAs) like warfarin. These patients are treated with aspirin, aspirin-clopidogrel combination
Gregory Y. H. Lip +9 more
core +1 more source